Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Estimated marginal means of EF, DT, E/e’ by treatment type based on Model 2 over the follow-up periods

From: Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study

Days

Model 2

EMM (95% CI)

Diff

p

Group 1 - EF (%)

0–14

65.6 (62.6;68.7)

0 (ref).

-

15–180

64.8 (61.7;67.9)

-0.8

0.431

181–365

64.4 (61.4;67.4)

-1.2

0.146

366–545

66.7 (63.5;69.8)

1.0

0.193

> 545

66.5 (63.4;69.7)

0.9

0.282

Group 1 - DT (msec)

0–14

215.9 (183.6;253.9)

0 (ref).

-

15–180

212.1 (179.8;250.1)

-3.9

0.123

181–365

210.8 (179.6;247.4)

-5.1

0.361

366–545

203.6 (172.6;240.3)

-12.4

0.768

> 545

206.4 (174.9;244)

-9.5

0.675

Group 1 - E/e’

0–14

6.6 (5.6;7.7)

0 (ref).

-

15–180

6.5 (5.6;7.6)

-0.1

0.329

181–365

6.8 (5.8;7.9)

0.2

0.838

366–545

7 (6;8.2)

0.4

0.402

> 545

6.8 (5.8;8)

0.2

0.869

Group 2 - EF (%)

0–14

65.5 (62.5;68.6)

0 (ref).

-

15–180

63.5 (60.5;66.6)

-2.0

0.093

181–365

62.1 (59;65.3)

-3.4

0.007

366–545

64.4 (60.9;67.9)

-1.2

0.415

> 545

64.6 (61.2;68.1)

-0.9

0.51

Group 2 - DT (msec)

0–14

227.9 (194;267.5)

0 (ref).

-

15–180

197.4 (168;231.8)

-30.6

0.028

181–365

206.2 (174.2;244.2)

-21.7

0.159

366–545

208.9 (171.9;253.9)

-19.0

0.294

> 545

209.6 (173.6;253.2)

-18.4

0.285

Group 2 - E/e’

0–14

6.7 (5.8;7.8)

0 (ref).

-

15–180

7.1 (6.1;8.3)

0.4

0.3

181–365

7 (6;8.3)

0.3

0.5

366–545

7.6 (6.4;9.1)

0.9

0.1

> 545

7 (5.8;8.5)

0.3

0.6

  1. Estimated marginal means based on linear mixed models. p < 0.05 was considered statistically significant. Group 1 included patients who received taxane-based chemotherapy treatment without anthracycline. Group 2 included patients who received anthracycline followed by taxane-based treatment. EMM, estimated marginal mean; 95% CI, 95% confidence interval; EF, ejection fraction; DT, deceleration time; E/ e’, ratio of early diastolic flow peak velocity of the mitral valve (E) and early diastolic peak velocity of mitral valve annulus (e’). First column shows the number of days since first chemotherapy. Column Diff shows the difference between EMMs of the given vs. the reference period (0–14 days). Model 2 was adjusted for age, body mass index, hypertension, diabetes mellitus, hyperlipidaemia, current smoking, major adverse cardiac events, and previous chemotherapy as fixed effects
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us